Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBleomycinBone Marrow PurgingCombined Modality TherapyCyclophosphamideCytarabineDisease ProgressionDisease-Free SurvivalDoxorubicinDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesGenes, bcl-2Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansImmunologic FactorsImmunosuppressive AgentsKaplan-Meier EstimateLymphoma, FollicularMaleMiddle AgedMultivariate AnalysisPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionRituximabTime FactorsTransplantation, AutologousTreatment OutcomeVincristineConceptsProgression-free survivalRefractory follicular lymphomaHigh-dose therapyFollicular lymphomaFive-year progression-free survivalPeripheral blood stem cell mobilizationBlood stem cell mobilizationEnd pointHigh-dose AraC.Persistent clinical remissionPrimary end pointSecondary end pointsStem cell harvestStem cell mobilizationBcl-2 rearrangementClinical remissionComplete remissionMolecular remissionPartial responseComplete responseClinical outcomesCell mobilizationMedian numberImmunochemotherapyPatients